# Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus

> **NCT03011008** · PHASE4 · UNKNOWN · sponsor: **Second Xiangya Hospital of Central South University** · enrollment: 20 (estimated)

## Conditions studied

- Type 1 Diabetes Mellitus
- Autoimmune Diabetes

## Interventions

- **DRUG:** Liraglutide
- **DRUG:** Insulin

## Key facts

- **NCT ID:** NCT03011008
- **Lead sponsor:** Second Xiangya Hospital of Central South University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01
- **Primary completion:** 2020-12
- **Final completion:** 2021-06
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2020-03-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03011008

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03011008, "Liraglutide as Additional Treatment to Insulin in Patients With Autoimmune Diabetes Mellitus". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03011008. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*